Supplementation with lecithin can improve skeletal muscle atrophy

Tibial muscular atrophy is a common hereditary disease in the peripheral nervous system. It has more than 2 million patients worldwide and is considered to be a rare and intractable disease. A collaboration between researchers at the Max Planck Institute for Experimental Medicine and the University of GÃ¶ttingen Medical Center found that a harmless food supplement called lecithin can treat and improve skeletal muscle atrophy. The research results are published in Nature. Newsletter magazine.

Due to genetic defects, doubling of the gene PMP22 causes progressive neuromuscular atrophy in the patient, a slow-moving nerve injury. The patient may have difficulty in walking, or a first-episode symptom such as a deformed foot in childhood. After that, there are sensory disturbances such as numbness, tingling and pain, and the strength of the legs and arms is gradually weakened. In severe cases, patients can only live in a wheelchair. So far, iliac muscle atrophy is still incurable because its disease mechanism is still unclear.

A membrane, called myelin, is wrapped around the axons of nerve cells and consists of Schwann cells and other types of nerve-supporting cells. Its function is to prevent the transmission of nerve impulses from neuronal axons to another neuron axon. This time, the researchers found that the fat metabolism of Schwann cells in the lesions was disturbed by the transgenic mouse experiment, and it could not form enough myelin. Patients with sacral muscular atrophy are due to abnormal metabolism of Schwann cells, resulting in functional disorders in many nerve fibers without myelin.

Further studies have found that lecithin can promote the production of fat in damaged Schwann cells, thereby improving myelination. Lecithin is a so-called phospholipid mixture derived from soy or egg yolk and is a harmless food supplement. As one of the research projects funded by the German Federal Ministry of Education and Research, the researchers first showed through cell culture experiments in transgenic mice that lecithin can be absorbed by Schwann cells and promote myelination. Dr. Stasat, the project leader of the Max Planck Institute for Experimental Medicine, said that the researchers have found that phospholipid therapy can not only promote myelination, but also to treat lecithin in different doses and treatment cycles. How the treatment begins can significantly reduce the disease progression, proving that lecithin can be used as an adjunct to the treatment of patellar muscular atrophy and other demyelinating diseases.

YT-M95

Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwinsz.com